ACITRETIN Drug Patent Profile
✉ Email this page to a colleague
When do Acitretin patents expire, and what generic alternatives are available?
Acitretin is a drug marketed by Alembic, Barr Labs Inc, Impax Labs Inc, Mylan, Norvium Bioscience, Sigmapharm Labs Llc, and Teva Pharms Usa. and is included in seven NDAs.
The generic ingredient in ACITRETIN is acitretin. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the acitretin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Acitretin
A generic version of ACITRETIN was approved as acitretin by BARR LABS INC on April 4th, 2013.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ACITRETIN?
- What are the global sales for ACITRETIN?
- What is Average Wholesale Price for ACITRETIN?
Summary for ACITRETIN
| US Patents: | 0 |
| Applicants: | 7 |
| NDAs: | 7 |
| Finished Product Suppliers / Packagers: | 8 |
| Raw Ingredient (Bulk) Api Vendors: | 119 |
| Clinical Trials: | 37 |
| Patent Applications: | 5,252 |
| Drug Prices: | Drug price information for ACITRETIN |
| What excipients (inactive ingredients) are in ACITRETIN? | ACITRETIN excipients list |
| DailyMed Link: | ACITRETIN at DailyMed |
Recent Clinical Trials for ACITRETIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Singapore General Hospital | Phase 4 |
| Translational Immunology Institute | Phase 4 |
| South Valley University | Phase 4 |
Pharmacology for ACITRETIN
| Drug Class | Retinoid |
Medical Subject Heading (MeSH) Categories for ACITRETIN
Anatomical Therapeutic Chemical (ATC) Classes for ACITRETIN
US Patents and Regulatory Information for ACITRETIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alembic | ACITRETIN | acitretin | CAPSULE;ORAL | 217774-001 | Aug 5, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Pharms Usa | ACITRETIN | acitretin | CAPSULE;ORAL | 202897-001 | Apr 4, 2013 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Impax Labs Inc | ACITRETIN | acitretin | CAPSULE;ORAL | 202552-002 | Dec 23, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Barr Labs Inc | ACITRETIN | acitretin | CAPSULE;ORAL | 091455-001 | Apr 4, 2013 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Norvium Bioscience | ACITRETIN | acitretin | CAPSULE;ORAL | 203707-001 | Sep 10, 2015 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Impax Labs Inc | ACITRETIN | acitretin | CAPSULE;ORAL | 202552-003 | Dec 23, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Pharms Usa | ACITRETIN | acitretin | CAPSULE;ORAL | 202897-002 | Apr 4, 2013 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
